Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.62 |
| ▸ | MIF | P14174 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097501 | 0.89 | F10 (0.62) | F10MIFCYP3A4CYP2C9ABCB11 | |
| SCHEMBL4911973 | 0.88 | F10 (0.55) | F10MIFCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1096808 | 0.81 | F10 (0.53) | F10MIFABCB11F2ST14 | |
| SCHEMBL1098231 | 0.80 | F10 (0.54) | F10MIFCYP3A4CYP2C9ABCB11 | |
| SCHEMBL1096902 | 0.78 | F10 (0.63) | F10CYP3A4CYP2C9ABCB11F2 | |
| SCHEMBL8243711 | 0.78 | F10 (0.41) | F10MIFCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL78508 | 0.77 | F10 (1.00) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19126463 | 0.76 | F10 (0.44) | F10L3MBTL1PTGS2 | |
| SCHEMBL19144958 | 0.75 | F10 (0.43) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1095716 | 0.74 | F10 (0.56) | F10MIFF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | DAHMANN GEORG | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051578-A1 | SUBSTITUTED BIARYLS, PROCESS FOR THEIR MANUFACTURE AND USE THEREOF AS MEDICAMENTS | CYP11B2, CYP3A43, CYP11B1 | F10 2414/4885MIF 3572/4885CYP1A2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.